IgA Nephropathy Insights

FDA Approves Atrasentan for IgA Nephropathy Proteinuria

April 09, 2025 • Estimated Reading Time: 1 minute

Latest Research

Epigenetic modifications play a crucial role in understanding kidney diseases like IgA nephropathy. Sasaki and Masaki (2025) These modifications involve changes in gene expression without altering the DNA sequence itself, affecting how genes are turned on or off. This can influence disease progression and provide insights into how IgA nephropathy develops.

Research highlights the role of histone-modifying enzymes in inducing specific types of methylation, leading to changes in chromatin structure and gene expression. Studying these mechanisms could uncover new targets for treating kidney diseases, potentially leading to better management strategies for conditions like IgA nephropathy by exploring how epigenetic changes influence disease outcomes (Sasaki & Masaki, 2025).

Clinical Trials

This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Study of WAL0921 in Patients With Glomerular Kidney Diseases

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

View the full list of clinical trials →

Community News

IgA Nephropathy FoundationApr 03, 2025

"Today's approval marks an important milestone for people living with IgA nephropathy, offering a new option that can be seamlessly integrated into their existing treatment plan, with no REMS requirement," said Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Glomerular Disease Center at Stanford University Medical Center, and Vanrafia ALIGN Study Investigator and Steering Committee Member. "Vanrafia is a selective ETA receptor antagonist that effectively reduces proteinuria, a major risk factor in IgAN. Taking early, decisive action is critical to help improve outcomes for these patients who too often progress toward kidney failure." source: Novartis.com

Our future looks bright. You are not alone. ❤️💙 As soon as we receive patient facing materials we will update this post and share with our IgAN Community.

Learn More